Compare Ascendis Pharma A/S (ASND) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Danaher Corporation — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while Danaher Corporation trades at $200.14 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 7.9× Ascendis Pharma A/S's market cap, and Danaher Corporation pays a 0.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DHR | |
|---|---|---|
Market Cap | $17.74B | $140.88B |
Sector | Health | Health |
52-Week High | $277.18 | $242.05 |
52-Week Low | $163.32 | $161.91 |
Enterprise Value | $18.11B | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Danaher (DHR) trades at $199.05, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest and profit margins have compressed from pandemic peaks. Recent business developments include the shareholder approval of the Masimo acquisition and new product launches in its SCIEX division, suggesting ongoing strategic investment.
The outlook is cautiously optimistic, supported by a dominant 'Buy' analyst consensus and a price target implying ~7% upside. Key opportunities lie in the firm's biotechnology segment strength and strategic M&A. Risks include ongoing margin pressure, integration challenges from acquisitions, and a relatively high valuation (P/E of 38.6) that demands sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
